Answers are grounded in this paper and cite their sources.
In vitro mRNA display reveals glycopeptides for P-selectin and asialoglycoprotein receptor, indicating new drug development pathways.
A robust method for the ribosomal incorporation of glycosyl-amino acids through the flexizyme-mediated reprogramming of initiating AUG codons with glycosyl-dipeptides is described. This reprogramming strategy was applied to in vitro mRNA display for the de novo discovery of α-l-fucosylated cyclic peptide inhibitors of P-selectin with antiplatelet-monocyte aggregation activity, and β-d-N-acetylgalactosamine-containing cyclic glycopeptide agonists of the asialoglycoprotein receptor (ASGPR) with potent lysosome trafficking activity. This work provides a powerful platform for the de novo discovery of glycopeptide ligands and expands genetic reprogramming capabilities to large modifications previously intractable for ribosomal translation.
No takes yet. Share an insight, caveat, or question.
Johansen-Leete et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: